Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced feedback from the United States Food and Drug Administration (FDA) on its clinical development plans for its PGN-600 program, and provided program updates.
For Biora’s Targeted Therapeutics Platform, which is focused on treatment of ulcerative colitis (UC), the company remains on track for an IND filing for its PGN-600 program followed by clinical trial initiation. During Q4 2022, Biora continued its engagement with the FDA with a pre-IND supplemental Type C filing requesting agency feedback on its proposed PGN-600 clinical development plans, including the company’s proposed approach to toxicity studies and other aspects of its clinical plan.
“The recent Type C response from the FDA further strengthens our confidence in our plans to enter the clinic during the first half of 2023 with IND filing followed by trial initiation in Q2, and data readouts anticipated in Q3,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “Based on previous studies, we know that achieving the appropriate concentration of tofacitinib in the tissue of the large intestine is correlated with endoscopic improvement, and we believe that reducing systemic exposure to tofacitinib could be a paradigm shift in the ability to help a substantial percentage of patients. Our planned clinical trial should provide insights on these very important tissue and plasma levels, along with the safety of our approach. With this critical data anticipated during the phase 1 trial, we look forward to progressing a program that could have significant impact on patient care for ulcerative colitis.”
Biora Therapeutics has previously shown the strong potential of its Targeted Therapeutics platform to help patients with ulcerative colitis (UC) through data demonstrating that:
- Higher tissue levels of tofacitinib in UC patients are correlated with endoscopic improvement.
- Biora’s device can accurately deliver liquid payload to the correct location in the colon of healthy volunteers.
- Biora’s device can accurately identify colon entry and deliver liquid payload to the site of disease in active ulcerative colitis patients, despite a challenging environment of inflammation, bleeding, and highly variable motility.
- Biora’s device can function as intended when administered both with and without food.
For Biora’s Systemic Therapeutics program, the company has been transitioning from early concept to a clinical-ready device. With several of the key device upgrades implemented, the company expects to report data from preclinical studies on its next-generation device during Q1 and Q2 of 2023.
“We are making good progress with our systemic therapeutics program and expecting additional bioavailability data in the coming months,” said Mr. Mohanty. “These data, if consistent with data from our previous version of the device, which showed average bioavailability of approximately 25% with a variant of adalimumab, should enable us to progress the relationships with our existing pharma collaborators, and potentially establish relationships with additional entities. Achieving meaningful partnerships based on our systemic platform is a fundamental goal for Biora in the coming year, with potential for multiple partnerships over time due to the broad applicability of the platform to different molecules.”
Key 2023 Milestones
- Present the first detailed results from the Targeted Therapeutics program device performance study indicating successful device function when administered with food, which could potentially enable non-fasted administration in patients, at the Crohn’s & Colitis Congress on January 19, 2023.
- File an IND for Targeted Therapeutics PGN-600 and enter the clinic in the first half of 2023.
- Generate key Targeted Therapeutics PGN-600 data by Q3.
- Complete Systemic Therapeutics preclinical data generation with the next generation device in Q1 and Q2.
- Initiate next-phase pharma partnerships for Systemic Therapeutics program in 2023.
Biora also remains committed to efficient use of resources by maintaining its target monthly cash burn rate while rapidly progressing development.